Compounds > vidarabine phosphate

vidarabine phosphate and Myelodysplastic Syndromes

vidarabine phosphate has been researched along with Myelodysplastic Syndromes in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Artz, A; De Lima, M; Giralt, S; Kunavakkam, R; Oran, B; Rondon, G; van Besien, K1
Catovsky, D; Dearden, C; Kochethu, G; MacConkey, C; Matutes, E; Milligan, DW1

Trials

2 trial(s) available for vidarabine phosphate and Myelodysplastic Syndromes

ArticleYear
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Vidarabine Phosphate; Young Adult

2009
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia.
    British journal of haematology, 2006, Volume: 133, Issue:2

    Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Transplantation Conditioning; Vidarabine Phosphate

2006